These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
325 related articles for article (PubMed ID: 3806749)
1. Disseminated cutaneous leishmaniasis in a field clinic in Bahia, Brazil: a report of eight cases. Costa JM; Marsden PD; Llanos-Cuentas EA; Netto EM; Carvalho EM; Barral A; Rosa AC; Cuba CC; Magalhães AV; Barreto AC J Trop Med Hyg; 1986 Dec; 89(6):319-23. PubMed ID: 3806749 [TBL] [Abstract][Full Text] [Related]
2. Antibody response in patients with cutaneous leishmaniasis infected by Leishmania (Viannia) braziliensis or Leishmania (Viannia) guyanensis in Brazil. Romero GA; de la Glória Orge Orge M; de Farias Guerra MV; Paes MG; de Oliveira Macêdo V; de Carvalho EM Acta Trop; 2005 Jan; 93(1):49-56. PubMed ID: 15589797 [TBL] [Abstract][Full Text] [Related]
3. Apparent Glucantime failure in five patients with mucocutaneous leishmaniasis. Rocha RA; Sampaio RN; Guerra M; Magalhâes A; Cuba CC; Barreto AC; Marsden PD J Trop Med Hyg; 1980 Aug; 83(4):131-9. PubMed ID: 6997505 [TBL] [Abstract][Full Text] [Related]
4. [Experimental chemotherapy in cutaneous leishmaniasis. III. Effect of glucantime and humatin (P&D) on Leishmania garnhami and Leishmania braziliensis in hamsters]. Rezzano S; Armas JA; Moreno G; Scorza JV Acta Cient Venez; 1984; 35(5-6):394-403. PubMed ID: 6537698 [No Abstract] [Full Text] [Related]
5. Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis. Azeredo-Coutinho RB; Mendonça SC; Callahan H; Portal AC; Max G J Parasitol; 2007 Jun; 93(3):688-93. PubMed ID: 17626365 [TBL] [Abstract][Full Text] [Related]
6. Development of Leishmania (Viannia) panamensis lesions and relationship of numbers of amastigotes to lesion area on antimony-treated and untreated hamsters. Hanson WL; Chapman WL; Waits VB; Lovelace JK J Parasitol; 1991 Oct; 77(5):780-3. PubMed ID: 1919929 [TBL] [Abstract][Full Text] [Related]
7. Intralesional glucantime in Leishmania braziliensis braziliensis infections. Barrios LA; Costa JM; Netto EM; Vexenat CO; Cuba CC; Marsden PD Trans R Soc Trop Med Hyg; 1986; 80(1):173-4. PubMed ID: 3726989 [No Abstract] [Full Text] [Related]
9. Alterations in phenotypic profiles of peripheral blood cells from patients with human American cutaneous leishmaniasis following treatment with an antimonial drug and a vaccine. Botelho AC; Mayrink W; Oliveira RC Acta Trop; 2009 Nov; 112(2):143-8. PubMed ID: 19631187 [TBL] [Abstract][Full Text] [Related]
10. Human american cutaneous leishmaniasis (Leishmania b. braziliensis) in Brazil: lymphoproliferative responses and influence of therapy. Mendonça SC; Coutinho SG; Amendoeira RR; Marzochi MC; Pirmez C Clin Exp Immunol; 1986 May; 64(2):269-76. PubMed ID: 3742876 [TBL] [Abstract][Full Text] [Related]
11. Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis. Andersen EM; Cruz-Saldarriaga M; Llanos-Cuentas A; Luz-Cjuno M; Echevarria J; Miranda-Verastegui C; Colina O; Berman JD Am J Trop Med Hyg; 2005 Feb; 72(2):133-7. PubMed ID: 15741547 [TBL] [Abstract][Full Text] [Related]
12. Immunotherapy as a treatment of American cutaneous leishmaniasis: preliminary studies in Brazil. Mayrink W; Magalhaes PA; Michalick MS; da Costa CA; Lima Ade O; Melo MN; Toledo VP; Nascimento E; Dias M; Genaro O Parassitologia; 1992 Dec; 34(1-3):159-65. PubMed ID: 1339971 [TBL] [Abstract][Full Text] [Related]
13. Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis. Arevalo J; Ramirez L; Adaui V; Zimic M; Tulliano G; Miranda-Verástegui C; Lazo M; Loayza-Muro R; De Doncker S; Maurer A; Chappuis F; Dujardin JC; Llanos-Cuentas A J Infect Dis; 2007 Jun; 195(12):1846-51. PubMed ID: 17492601 [TBL] [Abstract][Full Text] [Related]
14. Long-term follow-up of patients with Leishmania (Viannia) braziliensis infection and treated with Glucantime. Netto EM; Marsden PD; Llanos-Cuentas EA; Costa JM; Cuba CC; Barreto AC; Badaró R; Johnson WD; Jones TC Trans R Soc Trop Med Hyg; 1990; 84(3):367-70. PubMed ID: 2260171 [TBL] [Abstract][Full Text] [Related]
15. American cutaneous leishmaniasis: disappearance of amastigotes from lesions during antimonial therapy. Mayrink W; Raso P; Melo MN; Michalick MS; Magalhães PA; Williams P; da Costa CA; Dias M Rev Inst Med Trop Sao Paulo; 1983; 25(6):265-9. PubMed ID: 6672988 [No Abstract] [Full Text] [Related]
16. A comparative study between the efficacy of systemic meglumine antimoniate therapy with standard or low dose plus oral omeprazole in the treatment of cutaneous leishmaniasis. Nilforoushzadeh MA; Jaffary F; Ansari N; Siadat AH; Nilforoushan Z; Firouz A J Vector Borne Dis; 2008 Dec; 45(4):287-91. PubMed ID: 19248655 [TBL] [Abstract][Full Text] [Related]
17. Cutaneous leishmaniasis due to Leishmania (Leishmania) amazonensis in Amazonian Brazil, and the significance of a negative Montenegro skin-test in human infections. Silveira FT; Lainson R; Shaw JJ; De Souza AA; Ishikawa EA; Braga RR Trans R Soc Trop Med Hyg; 1991; 85(6):735-8. PubMed ID: 1801340 [TBL] [Abstract][Full Text] [Related]
18. [Cutaneous leishmaniasis]. Vion B Rev Med Suisse Romande; 1989 Jun; 109(6):443-9. PubMed ID: 2547241 [No Abstract] [Full Text] [Related]
19. Diffuse cutaneous leishmaniasis acquired in Peru. Franke ED; Lucas CM; Tovar AA; Kruger JH; De Rivera MV; Wignall FS Am J Trop Med Hyg; 1990 Sep; 43(3):260-2. PubMed ID: 2221221 [TBL] [Abstract][Full Text] [Related]
20. Mucosal leishmaniasis: description of case management approaches and analysis of risk factors for treatment failure in a cohort of 140 patients in Brazil. Amato VS; Tuon FF; Imamura R; Abegão de Camargo R; Duarte MI; Neto VA J Eur Acad Dermatol Venereol; 2009 Sep; 23(9):1026-34. PubMed ID: 19453817 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]